Adaptimmune reports early Phase I/II liposarcoma data for NY-ESO SPEAR T cells

Adaptimmune Therapeutics plc (NASDAQ:ADAP) said its NY-ESO SPEAR T cell therapy led to three partial responses and one case of stable disease in the first four patients with myxoid/round cell liposarcoma (MRCLS) in an open-label, U.S. Phase I/II trial. The company touched a 52-week high of $13.41 on March 15, and closed with a market cap above $1 billion.

The trial's primary endpoint is overall response rate (ORR). Secondary endpoints include time to first response, duration of response, duration of stable disease, progression-free survival (PFS), overall survival and safety. The company plans to present the data at an upcoming medical meeting...